Reading between the lines in the MD&A 1Q26: Sikarin Public Company Limited (SKR)
Sikarin PCL (SKR) net profit fell 39.3% to Bt125m in 1Q26, but the MD&A omits its Bt162m buyback's unresolved share resale decision.
Reading between the lines in the 1Q26 Management Discussion and Analysis of Sikarin Public Company Limited (SKR): Revenue down 8.3%. Net profit down 39.3%. And a Bt162m share buyback with an unresolved resale decision that is not referenced in 1Q26.
The numbers
Both patient segments soften
Sikarin is a private hospital operator in Thailand, running hospitals in Bangkok, Samut Prakan, and Hatyai. In 1Q26, total revenue fell 8.3% YoY to Bt1,404m, as revenue from Social Security Scheme patients fell 15.0% on fewer complex, high-cost surgical cases, and general patient service revenue fell 4.0%.
Costs hold firmer than revenue, margins compress
Gross margin fell to 27.0% in 1Q26 from 30.9% in 1Q25, as revenue declined faster than costs could adjust; the cost of medical treatment stood at 73.0% of medical service revenue in 1Q26. Selling and administrative expenses rose 3.8% YoY on higher building and facility repair costs. Net profit fell 39.3% to Bt125m, a net margin of 8.9% against 13.5% in 1Q25.
Equity builds on retained earnings
Total assets rose 1.2% to Bt9,671m, with current assets up 4.9%. Total shareholder equity rose 1.5% to Bt8,023m from Bt7,907m at FY25, broadly in line with net profit earned during the quarter.
What the numbers don’t show
Comparing the FY25 MD&A with 1Q26, a couple of things stand out.
A Bt162m buyback, completed with a resale decision still open, is not mentioned in 1Q26
The FY25 MD&A tracked a share repurchase program through 2025: approved in Q1 with a budget of up to Bt700m and up to 87,500,000 shares (4.3% of issued shares), and completed in Q3, when the Company repurchased 23,000,000 shares (1.1% of issued shares) for Bt162m. Regulations allow resale of the shares between six months and three years after completion, with unsold shares to be canceled once that window lapses. The 1Q26 MD&A’s summary of important events does not reference the buyback, the treasury shares, or any resale plan.
A 2050 Net Zero target appears in 1Q26; FY25 referenced only a 2027 goal
The FY25 MD&A’s sustainability section discussed a company greenhouse gas reduction target for 2027, tied to an electric vehicle charging expansion, alongside its SET ESG Ratings and corporate governance scores. It made no mention of a company-wide Net Zero target. The 1Q26 MD&A discloses that, following Thailand’s updated Nationally Determined Contribution submitted at COP30 in November 2025 advancing the national Net Zero target to 2050, the Company has revised its own Net Zero plan and targets to align with the national objective. Neither filing quantifies the Company’s Net Zero pathway or interim milestones.